• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.net
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

MarketIntelligence

VASRO GmbH > Press > MarketIntelligence
VASRO GmbH

The Rise of Personalized Medicine in 2025

  • February 26, 2025
  • Pharma & Biotech, Tech
Discover how pharmaceutical and biotechnology trends like AI, personalized medicine, and M&A are revolutionizing healthcare and patient outcomes in 2025.
Continue Reading
VASRO GmbH

Major Market Indices Performance Analysis for February 2025

  • February 25, 2025
  • Pharma & Biotech, Tech
Market Indices Performance Analysis for February 2025: Explore key trends in technology, energy, biotech, and pharmaceutical sectors and factors driving their shifts.
Continue Reading
VASRO GmbH

European Energy Stocks and Their Role in Shaping 2025 Market Trends

  • February 20, 2025
  • Unkategorisiert
European energy stocks, led by BP and Shell, are driving 2025 market trends with strategic shifts, influencing investor confidence and market stability.
Continue Reading
VASRO GmbH

Generative AI Success Stories in Drug Discovery

  • February 17, 2025
  • Pharma & Biotech, Tech
Generative AI is revolutionizing drug discovery and pharmaceutical R&D by accelerating timelines, reducing costs, and improving success rates with innovative solutions.
Continue Reading
VASRO GmbH

Why Equity Research Matters in the Era of AI Layoffs

  • February 14, 2025
  • Pharma & Biotech, Pharma & Biotech, Tech, Tech
AI layoffs and market shifts demand equity research to guide investors and companies. Discover how it identifies risks, opportunities, and ensures resilience.
Continue Reading
VASRO GmbH

A Comprehensive Guide to AI and Biotech Integration in 2025

  • February 13, 2025
  • Pharma & Biotech, Tech
Discover how the Biotech and Tech Industry Convergence in 2025 accelerates innovation, optimizes drug discovery, and ensures ethical AI governance.
Continue Reading
VASRO GmbH

Analyzing the Impact of Digitalization on Pharma in 2025

  • February 12, 2025
  • Pharma & Biotech, Tech
Discover how digital transformation is reshaping the pharma industry in 2025, driving innovation, efficiency, and aligning with Pharma Market Trends 2025.
Continue Reading
VASRO GmbH

The Impact of AI on Drug Development Strategies in 2025

  • February 11, 2025
  • Pharma & Biotech, Pharma & Biotech, Tech, Tech
AI revolutionizes drug development in 2025, enhancing efficiency, reducing costs, and driving innovation in the Drug Development Pipeline Insights 2025.
Continue Reading
VASRO GmbH

Johnson & Johnson Expands Neuroscience Portfolio with Intra-Cellular Therapies Acquisition

  • February 10, 2025
  • Pharma & Biotech
Johnson & Johnson's acquisition of Intra-Cellular Therapies enhances its neuroscience portfolio with CAPLYTA® and a robust pipeline, addressing critical mental health needs.
Continue Reading
VASRO GmbH

Why Patent Analysis Matters for Biotech Investors in 2025

  • February 7, 2025
  • Pharma & Biotech
Understand the importance of patent analysis in biotech investments to mitigate risks, secure market exclusivity, and identify innovation opportunities in 2025.
Continue Reading

Posts pagination

1 2 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY September 7, 2026
Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY August 31, 2026
Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update August 12, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • Info@vasro.net
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.